Eagle IP is excited to announce that Jennifer Che, President and Managing Director, will be attending the BIO 2025 International Conference, taking place from June 16-19 at the Boston Convention and Exhibition Centre. Jennifer will be participating in some events together with Hong Kong’s Science and Technology Park (HKSTP), who is hosting the Hong Kong Pavilion at BIO, sending a large delegation of attendees, as well as organizing several events.

This premier biotechnology event attracts over 17,000 professionals from around the globe, featuring networking opportunities, educational sessions, and an exhibition hall showcasing the latest innovations in the industry. Jennifer is looking forward to engaging with fellow attendees and exploring potential collaborations. She invites anyone attending the conference to reach out for a meeting to discuss opportunities, exchange ideas, or simply connect.

About BIO 2025
The BIO International Convention is the world’s largest biotechnology event, providing a platform for networking, learning, and collaboration. Attendees can participate in sessions covering the latest trends, regulatory updates, and scientific advancements, making it an invaluable experience for professionals in the biotech sector.

About Eagle IP
EAGLE IP is a specialized patent firm based in Greater China that facilitates the transfer of new technology from the research environment into the marketplace. Our team of Chinese and US patent practitioners possesses strong cross-border IP knowledge, industry experience, and deep technical expertise. We specialize in China patent strategy, patent drafting and prosecution, patent invalidations, cross-border IP issues, global patent portfolio strategy & management, and Hong Kong patent matters. Our management system is ISO 9001 certified for excellent quality control and management. Should you have any questions, please feel free to contact us at [email protected]

If you won’t be able to attend BIO 2025 but will be in Boston and would like to schedule a meeting, please let us know.

We are looking forward to seeing you in Boston!

我們過去活動

Recommended Insights

Markush claims in China - what can be arbitrarily deleted during invalidation?

2018年12月4日
Since 2010, the China Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that […]

SPC Upholds $2M RMB Award in China’s First Patent Case on a Biological Deposit

2022年7月4日
On 28 Feb 2022, China’s Supreme People’s Court (SPC) issued its annual “Judgment Digests”, which includes a list of “48 typical cases” highlighting representative SPC decisions in 2021. The Judgment Digests help us understand more about the SPC’s judicial ideology, trial concepts, and adjudication methods in dealing with difficult and sophisticated legal issues as well […]

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

2025年3月10日
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]

China Patent Office (CNIPA) Releases More Details About Patent Term Adjustment (PTA) in the Draft Examination Guidelines

2021年10月19日
The new 4th Amendment of the Chinese Patent Law came into effect on June 1, 2021. Right before that date, the Chinese Patent Office (“CNIPA”) released some “Interim Measures” to give us a taste of what was to come, though they have yet to released the actual Implementation Rules. Two months later, CNIPA finally released […]
Top crossarrow-right